Acrux (ASX:ACR) Retained Earnings : A$-117.73 Mil (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Acrux Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Acrux's retained earnings for the quarter that ended in Dec. 2023 was A$-117.73 Mil.

Acrux's quarterly retained earnings increased from Dec. 2022 (A$-117.02 Mil) to Jun. 2023 (A$-114.49 Mil) but then declined from Jun. 2023 (A$-114.49 Mil) to Dec. 2023 (A$-117.73 Mil).

Acrux's annual retained earnings declined from Jun. 2021 (A$-103.89 Mil) to Jun. 2022 (A$-113.72 Mil) and declined from Jun. 2022 (A$-113.72 Mil) to Jun. 2023 (A$-114.49 Mil).

Acrux Retained Earnings Historical Data

The historical data trend for Acrux's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acrux Retained Earnings Chart

Acrux Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Retained Earnings

Get a 7-Day Free Trial

-74.58

-83.87

-103.89

-113.72

-114.49

Acrux Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Retained Earnings	Get a 7-Day Free Trial															-109.36	-113.72	-117.02	-114.49	-117.73

Acrux Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Acrux (ASX:ACR) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Acrux (ASX:ACR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrux Ltd (ASX:ACR) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

ARUXF:USA FJY:Germany

Address

103-113 Stanley Street, West Melbourne, Melbourne, VIC, AUS, 3003

Website

https://www.acrux.com.au

Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone Topical Solution, and among others.